We export Chinese plasma-derived products and vaccines. Not general merchandise, not medical devices, not a little of everything. That narrowness is the whole point: this category punishes generalists at the point of registration.
Most confusion about our role disappears once the contracts are drawn. The supply contract is between the manufacturer and the distributor. We hold a service agreement and an export mandate. Nothing passes through our balance sheet.
The manufacturer authorises us in writing to represent a defined product scope in markets outside China. That authorisation is what we publish and what you can verify.
The import licence, the registration and the commercial relationship with the end user sit with you. You are the partner of record in your market, not a sub-agent.
Goods are invoiced by the manufacturer to you. We are paid a service fee for channel development, registration and export coordination.
We name them, list their listing status and publish their regulatory record — approval numbers included wherever the manufacturer has cleared publication. Most of it can be checked without asking us.
A central-SOE-backed plasma specialist based in Fuzhou, Jiangxi, spanning albumin, immunoglobulin and coagulation factor classes. The only manufacturer in the portfolio with a documented export record in plasma products.
Four plasma production bases and 23 collection centres, plus a licensed rabies vaccine (hamster kidney cell, S20000004). The group also runs IVD and scientific instrument divisions.
The only human vaccine industrialisation enterprise based in Guangzhou and part of the GPHL group. Single-product focus on freeze-dried rabies vaccine (Vero cell), formulated without gelatin, antibiotics or preservatives.
This is the method we apply on behalf of each manufacturer we represent. It is published here because factory export departments evaluate us on exactly this sequence.
Discuss a mandatePopulation, tender structure, existing registered competitors, local manufacturing protection and import licence availability. A market is only a target if a licensed partner exists and registration is feasible.
Cold chain first, licence second, route to end user third. We qualify the partner's infrastructure before discussing volumes, because a partner without 2–8 °C capability cannot become one later.
Dossier compiled to the destination authority's format, deficiencies answered in writing, artwork localised. This phase decides whether the territory ever produces revenue.
Batch documentation, temperature records, tender files and complaint routing. Most export relationships fail after the trial order, not before it — the second shipment is where support earns its fee.
Dossier compilation, authority correspondence, artwork and labelling compliance per market.
Batch documentation, certificate verification, deviation and complaint handling.
Export packing, domestic cold chain to the port, declaration, inspection and certificate legalisation.
Partner sourcing, territory terms, tender support and local market advisors.
Manufacturers and distributors reach the same team. Tell us which side of the table you are on and we will answer in kind.
